Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Acrobiosystems CoSZSE:301080 +8.58%92 Gross Margin % is 90.35% as of Mar. 2026, which is 1% below its 10-year median of 91.27. GuruFocus rates SZSE:301080 with a GF Score™ of 92/100 and a GF Value™ of ¥59.87 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 735 Biotechnology companies, Acrobiosystems Co ranks better than 85.17% on this metric.
Acrobiosystems Co (SZSE:301080) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Acrobiosystems Co had a gross margin of 90.35% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Acrobiosystems Co Gross Margin % Related Terms
Acrobiosystems Co Gross Margin % Historical Data
* Premium members only.
The historical data trend for Acrobiosystems Co's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SZSE:301080 vs VRTX, REGN, RVMD: Gross Margin % Comparison
For the Biotechnology subindustry, Acrobiosystems Co's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Acrobiosystems Co Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Acrobiosystems Co's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Acrobiosystems Co's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Acrobiosystems Co (SZSE:301080) has a Gross Margin % of 90.35% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Acrobiosystems Co and its competitors. This is near median its historical median of 91.27. Over the past decade, Acrobiosystems Co's Gross Margin % has ranged from 88.46 to 92.57. According to the industry distribution chart, Acrobiosystems Co ranks #109 out of 735 companies in the Biotechnology industry, placing it in the top 14.8%.
Is Acrobiosystems Co's Gross Margin % too high?
Acrobiosystems Co's current Gross Margin % of 90.35% is near median its 10-year median of 91.27. Over the past 10 years, this metric has ranged from a low of 88.46 to a high of 92.57. The Biotechnology industry median Gross Margin % is 60.90. Acrobiosystems Co's value of 90.35% is 48.4% above this industry median. Based on the distribution chart, Acrobiosystems Co ranks #109 out of 735 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Acrobiosystems Co has a GF Score™ of 92/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Acrobiosystems Co's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Acrobiosystems Co ranks #109 out of 735 companies for Gross Margin %. This places Acrobiosystems Co in the top 15% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 60.90. Acrobiosystems Co's value of 90.35% is 48.4% above this benchmark. Historically, Acrobiosystems Co's own Gross Margin % has ranged from 88.46 to 92.57 over the past decade. While the company's 10-year median is 91.27 vs. the industry median of 60.90, Acrobiosystems Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.90, based on 735 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Acrobiosystems Co's current Gross Margin % of 90.35% is 48.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Acrobiosystems Co and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Acrobiosystems Co's current Gross Margin % is 90.35%, which is near median its own 10-year median of 91.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acrobiosystems Co stock overvalued right now?
Based on GuruFocus' analysis, Acrobiosystems Co (SZSE:301080) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥59.87, compared to a current price of ¥89.25 — trading 49.1% above its estimated fair value. The current Gross Margin % is 90.35%, which is near median its 10-year median of 91.27 and 48.4% above the Biotechnology industry median of 60.90. Acrobiosystems Co's overall GF Score™ is 92/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Acrobiosystems Co (SZSE:301080), the current Gross Margin % is 90.35% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Acrobiosystems Co (SZSE:301080) Overvalued in 2026?
Based on GuruFocus' analysis, Acrobiosystems Co stock appears to be overvalued.
The current stock price of ¥89.25 is trading 49.1% above its estimated GF Value™ of ¥59.87.
GuruFocus considers Acrobiosystems Co to be Significantly Overvalued.
Key valuation signals for SZSE:301080:
Gross Margin %: 90.35% (near median its 10-year median of 91.27)
GF Value™: ¥59.87 vs. price of ¥89.25 (49.1% above fair value)
Industry Position: 48.4% above the Biotechnology median (#109 of 735)
No single metric tells the full story. See the SZSE:301080 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Acrobiosystems Co Ltd is a global brand focusing on protein technology, products and services in the development of biological drugs. It is committed to providing target antigens and other key reagents and related services required in the development of targeted therapeutic drugs.
92GF Score
Get the complete analysis for SZSE:301080
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SZSE:301080 has been successfully added to your 
